CapsulesClinical Overview
Silodosin (4mg/8mg) and Dutasteride (0.5mg) Capsules is an advanced fixed-dose combination for Benign Prostatic Hyperplasia (BPH). Silodosin is an ultra-selective alpha-1A adrenergic receptor antagonist (>160-fold selectivity over alpha-1B receptors), providing targeted bladder neck and prostatic relaxation with minimal vascular hypotensive effects. Dutasteride blocks both 5-alpha reductase isoforms, permanently lowering circulating and intraprostatic DHT to shrink prostate gland tissue. Indicated for treatment of moderate-to-severe LUTS associated with prostatic enlargement.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily with a meal (preferably dinner) with water. Swallow capsule whole. Take consistently with food to ensure optimal absorption and prevent dizziness.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Retrograde ejaculation (anejaculation occurs in >25-30% of patients), loss of libido, erectile dysfunction, mild dizziness, nasal congestion. Rare/Severe: Orthostatic hypotension, Intraoperative Floppy Iris Syndrome (IFIS), and gynecomastia.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
High incidence of retrograde ejaculation; reassure patient that orgasm sensation is preserved and the condition is reversible upon drug discontinuation. Contraindicated in severe hepatic impairment (Child-Pugh C) or severe renal impairment (CrCl < 30 mL/min). Pregnant women must never handle capsules.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, nephrological diagnosis, or urological treatment recommendations. Always consult a registered nephrologist, urologist, or qualified medical practitioner before initiating, modifying, or discontinuing any kidney or urinary tract medication.
Tamsulosin Hydrochloride (Modified Release) 0.4mg + Dutasteride 0.5mg Tablets
Tamsulosin Hydrochloride (0.4mg modified-release) and Dutasteride (0.5mg) Tablets/Capsules is a synergistic dual-action therapy on the WHO Model List framework for symptomatic Benign Prostatic Hyperplasia (BPH). Tamsulosin is a uroselective alpha-1A/1D adrenergic receptor antagonist that relaxes smooth muscle in the prostate stroma, prostatic capsule, and bladder neck, rapidly improving urinary peak flow rates and relieving lower urinary tract symptoms (LUTS). Dutasteride is a potent dual type 1 and type 2 5-alpha reductase inhibitor (5-ARI) that suppresses dihydrotestosterone (DHT) synthesis by >90%, progressively shrinking enlarged prostate volume over 3-6 months. Indicated for moderate-to-severe BPH with enlarged prostate (volume >30cc) to reduce the risk of acute urinary retention (AUR) and the need for BPH-related surgery (TURP).
Alfuzosin 10mg + Dutasteride 0.5mg Tablets
Alfuzosin (10mg prolonged-release) and Dutasteride (0.5mg) Tablets is a fixed-dose combination combining a functionally uroselective alpha-1 blocker with a dual 5-alpha reductase inhibitor. Alfuzosin relaxes prostatic smooth muscle and decreases bladder outlet resistance without inhibiting alpha-1A subtype exclusively, preserving normal ejaculation in most men. Dutasteride halts DHT-mediated androgenic proliferation, reducing prostate volume. Indicated for symptomatic BPH with enlarged prostate gland.
Dutasteride Capsule 0.5 mg
Dutasteride Capsules (0.5mg) is a synthetic 4-aza-steroid dual inhibitor of both type 1 and type 2 5-alpha-reductase isoenzymes on the WHO Model List of Essential Medicines. It blocks the enzymatic intracellular conversion of testosterone to 5-alpha-dihydrotestosterone (DHT) in the prostate, skin, and liver, suppressing circulating DHT levels by >90% and intraprostatic DHT by >94%. This induces apoptotic involution of prostatic epithelial cells, progressively reducing total prostate volume by ~25% and reducing risk of urinary retention and TURP surgery. Indicated for treatment of symptomatic BPH in men with enlarged prostate.
Silodosin Capsules 4 mg
Silodosin Capsules (4mg, 8mg) is an ultra-selective alpha-1A adrenergic receptor antagonist on the PMBI formulary. It demonstrates an extraordinarily high alpha-1A to alpha-1B binding affinity ratio (162:1), targeting the lower urinary tract smooth muscle with surgical precision while sparing vascular alpha-1B receptors that regulate arterial blood pressure. This confers excellent cardiovascular safety and minimal postural hypotension. Indicated for the treatment of the signs and symptoms of Benign Prostatic Hyperplasia (BPH) in adult men.